CorVel Corp

CorVel Corp (CRVL) Stock Analysis

$79.720

+0.032 (+0.04%)At close

Loading chart…
High
80.420
Open
79.320
VWAP
79.58
Volume
134.16K
Mkt Cap
4.32B
Low
78.586
Amount
10.68M
EV/EBITDA, TTM
0.00

CorVel Corporation applies technology, including artificial intelligence, machine learning and natural language processing, to enhance the management of episodes of care and the related health-care costs. The Company partners with employers, third-party administrators, insurance companies and government agencies to assist its customers in managing the medical costs of workers compensation, group health and auto insurance, and in monitoring the quality of care provided to claimants. Its services include claims management, bill review, preferred provider networks, utilization management, case management, pharmacy services, directed care and Medicare services. It delivers its solutions in three ways - as a fully integrated claims-management program, as discrete standalone services, or as targeted add-ons that enhance an existing client workflow. Integrated, end-to-end bundled programs are designed primarily for buyers such as self-insured employers who want a single, turnkey partner.

AI analysis of CorVel Corp (CRVL)

Buy

CorVel Corp is a good buy right now due to its recent strong financial performance, with a Q1 net profit of $32.22 million and an EPS of $0.63, both showing significant year-over-year growth. Additionally, the RSI is at 77.48, indicating strong momentum, while the stock has shown a 21.22% year-to-date increase, reflecting positive market sentiment. The main risk is the high forward P/E of 23.75, suggesting that the stock may be overvalued if growth expectations are not met.

Valuation Metrics

The current forward P/E ratio for CorVel Corp (CRVL) is 23.75, compared to its 5-year average forward P/E of 91.13.

Forward P/E

Undervalued
5Y Average P/E
91.13
Current P/E
23.75
Overvalued
130.81
Undervalued
51.45

Forward EV/EBITDA

Strongly Undervalued
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued
0.00
Undervalued
0.00

Forward P/S

Strongly Undervalued
5Y Average P/S
7.01
Current P/S
0.00
Overvalued
8.93
Undervalued
5.09

Whales holding CRVL

K

Kayne Anderson Rudnick Investment Management, LLC

+ HoldingCRVL

-3.23%

3M Return

Events Timeline

2026-06-01 (ET)

16:40:00

CorVel Appoints Sarah Scott as CEO

2026-05-20 (ET)

06:20:00

Q4 Revenue Reaches $248.54M

2026-02-03 (ET)

06:20:00

Q3 Revenue Reaches $236M vs. $228M Last Year

2025-02-13 (ET)

06:36:59

CorVel appoints Scott as Executive Vice President of Product

2024-12-24 (ET)

12:16:10

CorVel announces effectiveness of three-for-one forward stock split

News

CRVL FAQ — answered by Alphio AI

CorVel Corporation applies technology, including artificial intelligence, machine learning and natural language processing, to enhance the management of episodes of care and the related health-care costs. The Company partners with employers, third-party administrators, insurance companies and government agencies to assist its customers in managing the medical costs of workers compensation, group health and auto insurance, and in monitoring the quality of care provided to claimants. Its services include claims management, bill review, preferred provider networks, utilization management, case management, pharmacy services, directed care and Medicare services. It delivers its solutions in three ways - as a fully integrated claims-management program, as discrete standalone services, or as targeted add-ons that enhance an existing client workflow. Integrated, end-to-end bundled programs are designed primarily for buyers such as self-insured employers who want a single, turnkey partner. It operates in the Healthcare sector (INSURANCE AGENTS, BROKERS & SERVICE industry).

CorVel Corp is a good buy right now due to its recent strong financial performance, with a Q1 net profit of $32.22 million and an EPS of $0.63, both showing significant year-over-year growth. Additionally, the RSI is at 77.48, indicating strong momentum, while the stock has shown a 21.22% year-to-date increase, reflecting positive market sentiment. The main risk is the high forward P/E of 23.75, suggesting that the stock may be overvalued if growth expectations are not met.

Community

More ↗

No posts yet

Sign up or log in to join the discussion

This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.

Start trading